Impact BioMedical, INC. Interest Expense
Impact BioMedical, INC. (IBO) reported Interest Expense of $793.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-03-11
- Impact BioMedical, INC. interest expense for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Impact BioMedical, INC. interest expense for the quarter ending 2025-09-30 was $262.00K, a 14.10% decline year-over-year.
- Impact BioMedical, INC. interest expense for the quarter ending 2025-06-30 was $260.00K, a 0.38% decline year-over-year.
- Impact BioMedical, INC. interest expense for the quarter ending 2025-03-31 was $271.00K, a 17.83% increase year-over-year.
- Impact BioMedical, INC. interest expense for fiscal 2025 was $793.00K, a 25.54% decline from fiscal 2024.
- Impact BioMedical, INC. interest expense for fiscal 2024 was $1.06M, a 139.86% increase from fiscal 2023.
- Impact BioMedical, INC. interest expense for fiscal 2023 was $444.00K, a 3.90% decline from fiscal 2022.
- Impact BioMedical, INC. interest expense for fiscal 2022 was $462.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $262.00K derived: sum of 2 quarters · filed 2026-03-11 | $522.00K derived: sum of 3 quarters · filed 2026-03-11 | $793.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $262.00K 10-Q · filed 2025-11-07 | $522.00K derived: sum of 2 quarters · filed 2025-11-07 | $793.00K 10-Q · filed 2025-11-07 | $1.06M derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-06-30 | $260.00K 10-Q · filed 2025-08-14 | $531.00K 10-Q · filed 2025-08-14 | $801.00K derived: sum of 3 quarters · filed 2026-03-11 | $1.11M derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-03-31 | $271.00K 10-Q · filed 2025-05-14 | $541.00K derived: sum of 2 quarters · filed 2026-03-11 | $846.00K derived: sum of 3 quarters · filed 2026-03-11 | $1.11M derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $575.00K derived: sum of 2 quarters · filed 2026-03-11 | $836.00K derived: sum of 3 quarters · filed 2026-03-11 | $1.06M 10-K · filed 2026-03-11 |
| 2024-09-30 | $305.00K 10-Q · filed 2025-11-07 | $566.00K derived: sum of 2 quarters · filed 2025-11-07 | $795.00K 10-Q · filed 2025-11-07 | $921.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $261.00K 10-Q · filed 2025-08-14 | $491.00K 10-Q · filed 2025-08-14 | $616.00K derived: sum of 3 quarters · filed 2025-08-14 | $718.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $230.00K 10-Q · filed 2025-05-14 | $355.00K derived: sum of 2 quarters · filed 2025-05-14 | $457.00K derived: sum of 3 quarters · filed 2025-05-14 | $573.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $227.00K derived: sum of 2 quarters · filed 2025-03-28 | $343.00K derived: sum of 3 quarters · filed 2025-03-28 | $444.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $102.00K 10-Q · filed 2024-11-12 | $218.00K derived: sum of 2 quarters · filed 2024-11-12 | $319.00K 10-Q · filed 2024-11-12 | $418.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $116.00K 10-Q · filed 2024-08-13 | $217.00K 10-Q · filed 2024-08-13 | $316.00K derived: sum of 3 quarters · filed 2024-08-13 | $408.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $101.00K 10-Q · filed 2024-05-10 | $200.00K derived: sum of 2 quarters · filed 2024-05-10 | $292.00K derived: sum of 3 quarters · filed 2024-05-10 | $431.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $191.00K derived: sum of 2 quarters · filed 2024-02-20 | $330.00K derived: sum of 3 quarters · filed 2024-02-20 | $462.00K 10-K · filed 2024-02-20 |
| 2022-09-30 | $92.00K 10-Q · filed 2023-11-13 | $231.00K derived: sum of 2 quarters · filed 2023-11-13 | $363.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $139.00K 10-Q · filed 2023-10-05 | $272.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |